"Jaakkola, Panu" - Selaus tekijän mukaan TUNICRIS-julkaisut
Viitteet 1-3 / 3
-
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors : The phase I/II first-in-human MATINS trial
(19.12.2023)
articleMacrophage Clever-1 contributes to impaired antigen presentation and suppression of anti-tumor immunity. This first-in-human trial investigates the safety and tolerability of Clever-1 blockade with bexmarilimab in patients ... -
Systemic blockade of clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors : Results from a phase I/II clinical trial
(2021)
articlePurpose: Macrophages are critical in driving an immunosuppressive tumor microenvironment that counteracts the efficacy of T-cell–targeting therapies. Thus, agents able to reprogram macrophages toward a proinflammatory state ... -
Transportable system enabling multiple irradiation studies under simultaneous hypoxia in vitro
(13.11.2018)
articleBackground Cells in solid tumours are variably hypoxic and hence resistant to radiotherapy - the essential role of oxygen in the efficiency of irradiation has been acknowledged for decades. However, the currently available ...
